Elevated cholesterol levels, especially low lipoprotein cholesterol (LDL-C), leads to atherosclerosis—which may increase the risk of heart attack, stroke, and peripheral artery disease. Statins are common medications that can help lower cholesterol levels. However, myopathy can be a serious side effect that prevents patients from taking statins and significantly decreases overall quality of life. Described herein are dosage forms containing select combinations of natural herbal extracts and phytonutrients having the surprising ability to lower LDL-C levels in amounts comparable to statin drugs without noted side effects such as myopathy.

Elevated cholesterol levels, especially low lipoprotein cholesterol (LDL-C), leads to atherosclerosis—which may increase the risk of heart attack, stroke, and peripheral artery disease. Statins are common medications that can help lower cholesterol levels. However, myopathy can be a serious side effect that prevents patients from taking statins and significantly decreases overall quality of life. Described herein are dosage forms containing select combinations of natural herbal extracts and phytonutrients having the surprising ability to lower LDL-C levels in amounts comparable to statin drugs without noted side effects such as myopathy.

The present invention relates to a composition comprising a mixed alcoholic extract of eighteen botanical ingredients formulated into capsules for the treatment of H1N1 flu, strep, pneumonia, and Covid-19.

The present invention relates to a composition comprising a mixed alcoholic extract of eighteen botanical ingredients formulated into capsules for the treatment of H1N1 flu, strep, pneumonia, and Covid-19.

The present invention relates to a composition comprising a mixed alcoholic extract of eighteen botanical ingredients formulated into capsules for the treatment of H1N1 flu, strep, pneumonia, and Covid-19.

Exemplary embodiments relate to a manufacturing method of herbal medicine processed food. The method comprises (a) drying raw materials of Leonurus japonicus Houtt, Dioscorea bulbifera, Solanum nigrum L, Scutellaria baicalensis, Akebiae Caulis, corn silk, Astragalus membranaceus, Pueraria lobata Ohwi, and Lithospermum erythrorhizon by means of vacuum drying, wherein the drying temperature is 20 to 80° C., (b) grinding each of the vacuum-dried raw material of the step (a) to produce powder, (c) shaping mixture of powder of the step (b) into a round shape.

Exemplary embodiments relate to a manufacturing method of herbal medicine processed food. The method comprises (a) drying raw materials of Leonurus japonicus Houtt, Dioscorea bulbifera, Solanum nigrum L, Scutellaria baicalensis, Akebiae Caulis, corn silk, Astragalus membranaceus, Pueraria lobata Ohwi, and Lithospermum erythrorhizon by means of vacuum drying, wherein the drying temperature is 20 to 80° C., (b) grinding each of the vacuum-dried raw material of the step (a) to produce powder, (c) shaping mixture of powder of the step (b) into a round shape.

Exemplary embodiments relate to a manufacturing method of herbal medicine processed food. The method comprises (a) drying raw materials of Leonurus japonicus Houtt, Dioscorea bulbifera, Solanum nigrum L, Scutellaria baicalensis, Akebiae Caulis, corn silk, Astragalus membranaceus, Pueraria lobata Ohwi, and Lithospermum erythrorhizon by means of vacuum drying, wherein the drying temperature is 20 to 80° C., (b) grinding each of the vacuum-dried raw material of the step (a) to produce powder, (c) shaping mixture of powder of the step (b) into a round shape.

Provided is a kit comprising a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive; and a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof, and uses thereof in the treatment of pelvic pain arising from the female reproductive system. Further provided are methods of treatment of pelvic pain arising from a female reproductive system during a menstrual cycle, the method comprising administering during a first fraction of said menstrual cycle a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive, and administering during a second fraction of said menstrual cycle a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof.

Provided is a kit comprising a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive; and a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof, and uses thereof in the treatment of pelvic pain arising from the female reproductive system. Further provided are methods of treatment of pelvic pain arising from a female reproductive system during a menstrual cycle, the method comprising administering during a first fraction of said menstrual cycle a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive, and administering during a second fraction of said menstrual cycle a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof.